NCT00868660

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

A Phase I, Double Blind, Placebo-Controlled Study of ZP1848 Administered as Subcutaneous Bolus Injections in Healthy Subjects Followed by Multiple Doses in Patients With Crohn's Disease in Remission

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Zealand Pharma · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Healthy Normal Single Ascending Dose and Crohn's patient Multiple Ascending Dose

Detailed description

A Phase I, Double blind, Placebo-controlled, safety and tolerability study of ZP1848 administered as Ascending single Dose, SUBCUTANEOUS bolus injections in healthy SUBJECTS followed by a Multiple Dose cohort of patients with stable Crohn's disease in remission

Conditions

• Inflammatory Bowel Disease

Interventions

Type	Name	Description
DRUG	ZP1848	sc. bolus

Timeline

• Start date: 2009-01-01
• Primary completion: 2010-02-01
• Completion: 2010-02-01
• First posted: 2009-03-25
• Last updated: 2010-11-02

Locations

1 site across 1 country: United States